$Intellia(NTLA)$ Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress
-- Established proof of concept for the Company's modular in vivo delivery
platform with first-ever clinical data from systemically administered
CRISPR genome editing candidate in humans
-- Interim Phase 1 data from first two cohorts show NTLA-2001 was
well-tolerated and achieved deep TTR reduction, with a maximum 96% serum
TTR reduction by day 28, demonstrating potential as single-dose treatment
for transthyretin (ATTR) amyloidosis; plan to report additional data from
ongoing study this year
-- Plans to initiate first-in-human studies for both NTLA-2002 for
hereditary angioedema (HAE) and NTLA-5001 for acute myeloid leukemia
(AML) this year
-- Launched CAR T-cell company with Blackstone Life Sciences and Cellex Cell
Professionals; concurrent agreement with Cellex gives Intellia access to
donor cells and dedicated manufacturing capacity to support wholly-owned
ex vivo portfolio
-- Ended the quarter with strong cash position of $551.3 million, and raised
an additional $648.1 million of net proceeds from follow-on offering in
July